StockNews.com began coverage on shares of OpGen (NASDAQ:OPGN – Free Report) in a research report sent to investors on Monday. The firm issued a sell rating on the medical research company’s stock.
OpGen Price Performance
Shares of OpGen stock opened at $1.86 on Monday. The company’s 50-day moving average price is $2.18 and its 200-day moving average price is $3.51. OpGen has a 12-month low of $1.61 and a 12-month high of $38.40.
OpGen (NASDAQ:OPGN – Get Free Report) last posted its earnings results on Monday, August 19th. The medical research company reported ($1.18) earnings per share for the quarter. OpGen had a negative return on equity of 1,827.76% and a negative net margin of 1,140.36%. The firm had revenue of $0.03 million for the quarter.
Institutional Trading of OpGen
About OpGen
OpGen, Inc, a precision medicine company, engages in developing and commercializing molecular microbiology solutions in the United States and internationally. Its product portfolio includes Acuitas AMR Gene Panel, an in vitro diagnostic (IVD) test for the detection and identification of various bacterial nucleic acids and genetic determinants of antimicrobial resistance (AMR) from bacterial colonies isolated from any specimen, as well as Curetis CE-IVD-marked polymerase chain reaction-based SARS-CoV-2 test kits.
Read More
- Five stocks we like better than OpGen
- Canadian Penny Stocks: Can They Make You Rich?
- When Is the Best Time to Invest in Mutual Funds?
- Why Are Stock Sectors Important to Successful Investing?
- Is NVIDIA Stock in a Correction or Consolidation?
- Top Biotech Stocks: Exploring Innovation Opportunities
- 3 Oversold Stocks with Big RSI Rebound Potential
Receive News & Ratings for OpGen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for OpGen and related companies with MarketBeat.com's FREE daily email newsletter.